Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of sunitinib in von Hippel-Lindau disease
2009-013052-76Phase 2Completed
- Sponsor
- ARTIC
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in von Hippel–Lindau disease (VHL), sponsored by ARTIC. Primary endpoint: Objective response rate. Started Nov 2009; status: completed.
02
Drugs
sunitinib
03
Conditions
von Hippel–Lindau disease (VHL)
Beyond the preview
Go deeper on 2009-013052-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013052-76.